Medline Inc. announces launch of secondary offering of Class A common stock
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Medline (MDLN) announced that selling stockholders have launched an underwritten secondary offering of 60,000,000 shares of its Class A common stock. The sellers include affiliates of Blackstone, Carlyle and Hellman & Friedman, alongside GIC and its managed affiliate and an Abu Dhabi Investment Authority subsidiary. They intend to grant underwriters a 30-day option for up to 9,000,000 additional shares. Medline is selling no shares and will receive no proceeds.
Medline and Medline Holdings agreed to repurchase $200 million of Class A shares and limited partnership interests directly from the sellers at the price paid by underwriters. The repurchase is expected to close concurrently with, and depends on, the offering closing; the reverse condition does not apply. The offering registration statement is not yet effective.
Positive
- Minor point$200 million repurchase agreed for Class A shares and partnership interests, counting toward Medline’s existing repurchase program.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.No offering proceeds will go to Medline; selling stockholders are selling all offered shares.
- Minor pointRepurchase depends on the offering closing; the offering does not depend on the repurchase.
- Minor pointRegistration statement is not yet effective; securities cannot be sold before effectiveness.
News Explained
If the agreed repurchase closes, then for every Medline Holdings limited partnership interest bought from a selling stockholder, that seller also transfers an equivalent number of Medline Class B shares to Medline for cancellation, with no additional consideration.
Key Figures
- Shares offered
- 60,000,000 shares
- Secondary offering by selling stockholders
- Underwriters’ option
- Up to 9,000,000 shares
- 30-day option to purchase additional shares
- Repurchase
- $200 million
- Agreed repurchase from selling stockholders at the offering price per equity interest
Previous Offering Reports
-
A prior launch covered 60 million shares plus a 9 million-share option; the reported reaction was -3.85%.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
underwritten public offering financial
registration statement regulatory
limited partnership interests financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORTHFIELD, Ill., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today that certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc. and Hellman & Friedman LLC along with GIC Private Limited and its managed affiliate and a wholly owned subsidiary of the Abu Dhabi Investment Authority (collectively, the “Selling Stockholders”) have commenced an underwritten public offering of 60,000,000 shares of Medline’s Class A common stock (the “Offering”) pursuant to a registration statement filed with the Securities and Exchange Commission (the “SEC”). Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 9,000,000 shares of Medline’s Class A common stock.
Medline is not selling any shares of Class A common stock in the Offering and will not receive any of the proceeds from the sale.
Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers, and Blackstone Capital Markets and Carlyle are acting as co-managers for the proposed Offering.
The proposed Offering of these securities will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to this Offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.
In addition, Medline announced that it and Medline Holdings, LP (“Medline Holdings”) have agreed to repurchase an aggregate of
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar conditional or future expressions, are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements related to Medline’s industry, business strategy, costs, and cost savings, goals and expectations, market position, future operations, margins, profitability, annual guidance, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainties, and changes in circumstances, many of which are beyond Medline’s control, that could cause actual results to differ materially.
Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.
Contacts:
Investor relations:
Karen King
Global Head, Investor Relations
Patrick Flaherty
Director, Investor Relations
+1.847.247.7222
IR@medline.com
Media relations:
Ben Fox
Vice President, Corporate Communications
+1.224.327.9999
media@medline.com
Source: Medline Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of Medline’s $200 million repurchase?
Medline and Medline Holdings agreed to repurchase an aggregate of $200 million of Class A shares and limited partnership interests directly from selling stockholders at the price paid by underwriters in the offering. The repurchase is expected to close concurrently with the offering and is conditional on its closing, but the offering can close without the repurchase.